I totally agree with TDA and bioQLD here.
I'm "glad" that I can top up below 0.17, did not think it would happen again.
At Aruc, I disagree that "the market is punishing for not delivering", for 2 reasons.
- Market is made of SH who decide to sell (or not), and the volumes are so low, it's not like SH are abandoning the ship.
- RGS has actually been delivering consistently on their business plan: patents, clinical trials, deals. There is a delay for this Progenza deal in Japan, but is a 6-month delay a real issue when so much is at stake?
In hindsight, management did the right thing to negotiate a cash facility / loan based on the R&D tax rebate. It is enabling them to negotiate the best deal possible, rather than any deal to speed up AGC milestone payment. Well done.
Finally, the upside for Sygenus is such, that any share below 0.25 is a bargain right now.
Having said that, I understand that some SH sell when they see it fit. That's their cash management issue, not a punishment of RGS strategy.
Expand
